HIGH-GRADE B-CELL LYMPHOMA
Clinical trials for HIGH-GRADE B-CELL LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new HIGH-GRADE B-CELL LYMPHOMA trials appear
Sign up with your email to follow new studies for HIGH-GRADE B-CELL LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Experimental NK cell cocktail aims to outsmart resistant lymphoma
Disease control Not yet recruitingThis early-phase trial tests a combination of two antibody drugs (rituximab and tafasitamab) plus donated natural killer (NK) immune cells for people with B-cell non-Hodgkin lymphoma that has returned or not responded to at least two prior treatments. Up to 15 participants will r…
Matched conditions: HIGH-GRADE B-CELL LYMPHOMA
Phase: PHASE1 • Sponsor: Paolo Caimi, MD • Aim: Disease control
Last updated May 26, 2026 06:30 UTC
-
New drug trio aims to replace chemo for aggressive lymphoma
Disease control Not yet recruitingThis study tests a combination of three targeted drugs (polatuzumab vedotin, glofitamab, and tafasitamab) as a first treatment for people with aggressive B-cell lymphomas. The goal is to see if this chemo-free approach can shrink tumors effectively while causing fewer side effect…
Matched conditions: HIGH-GRADE B-CELL LYMPHOMA
Phase: PHASE2 • Sponsor: Brown University • Aim: Disease control
Last updated May 26, 2026 06:19 UTC
-
New study to track brain health in lymphoma patients after CAR-T therapy
Knowledge-focused Not yet recruitingThis study follows 100 adults with certain types of lymphoma who are receiving CAR-T cell therapy. Researchers will test their thinking, memory, and quality of life before treatment and again at 6, 12, and 24 months after. The goal is to understand how the therapy affects brain f…
Matched conditions: HIGH-GRADE B-CELL LYMPHOMA
Sponsor: Fondazione Italiana Linfomi - ETS • Aim: Knowledge-focused
Last updated May 26, 2026 04:37 UTC
-
15-Year Check-In: how long do modified immune cells last?
Knowledge-focused Not yet recruitingThis study follows 18 people who already received GF-CART01, a CAR T-cell therapy for certain blood cancers like lymphoma. Researchers will monitor participants for up to 15 years to see how long the modified cells stay in the body and whether any serious side effects appear. No …
Matched conditions: HIGH-GRADE B-CELL LYMPHOMA
Sponsor: GenomeFrontier Therapeutics TW Co., Ltd. • Aim: Knowledge-focused
Last updated May 20, 2026 11:57 UTC